Evaluating SCUBE-1 as Predictive Biomarker for Hypertension-Mediated Organ Damage: A Comparative Study

评估 SCUBE-1 作为高血压介导的器官损伤预测生物标志物的价值:一项比较研究

阅读:1

Abstract

BACKGROUND: Hypertension-mediated organ damage (HMOD) is a critical complication of hypertension that can present with cardiac, retinal, and renal manifestations and affect patient outcomes. Serum signal peptide, CUB (complement C1r/C1s, Uegf, and Bmp1) domain, and epidermal growth factor-like domain-containing protein 1 (SCUBE-1), a novel biomarker implicated in vascular pathology, shows promise for detecting HMOD. This study aims to explore the relation between SCUBE-1 levels and HMOD in hypertensive patients. METHODS: This cross-sectional study included 115 participants, comprising 79 hypertensive patients and 36 healthy controls. The hypertensive patients were divided into two groups based on HMOD presence. SCUBE-1 levels were measured to evaluate their diagnostic utility in detecting HMOD. RESULTS: Hypertensive patients exhibited significantly higher SCUBE-1 levels than controls (160.70 ng/mL vs. 75.64 ng/mL, p < 0.001). Among these patients, those with HMOD (cardiac, retinal, and renal) displayed even higher SCUBE-1 levels (311.27 ng/mL, range 137.86-460 ng/mL) compared to those without HMOD (142.53 ng/mL, range 110.56-178.19 ng/mL). Receiver operating characteristic curve analysis indicated that SCUBE-1 levels have significant diagnostic potential for differentiating between hypertensive patients with and without HMOD with area under the curve values of 0.722 for cardiac, 0.761 for retinal, and 0.707 for renal damage. CONCLUSIONS: Our study has revealed that SCUBE-1 levels are significantly elevated in hypertensive patients, particularly those with HMOD. The findings support the potential of SCUBE-1 as a valuable biomarker for predicting organ damage in hypertensive patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。